Photo from ESTRO/X
Jun 10, 2024, 12:19
Results from the TRAP trial presented at ESTRO24
ESTRO shared on X/Twitter:
“Results from the TRAP trial presented at ESTRO24: this phase-II trial explores the addition of SBRT to androgen receptor pathway inhibitor treatment in patients with oligoprogressive castrate-resistant prostate cancer.”
Source: ESTRO/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 27, 2024, 18:17
Sep 27, 2024, 17:14
Sep 27, 2024, 16:58
Sep 27, 2024, 16:57
Sep 27, 2024, 16:57